Status:
COMPLETED
Cardiac Biomarkers and Iron Status in Hemodialysis Patients
Lead Sponsor:
Tungs' Taichung Metroharbour Hospital
Conditions:
Heart Failure
Iron-deficiency
Eligibility:
All Genders
20+ years
Brief Summary
Background: Peripheral arterial disease (PAD) a condition characterized by atherosclerotic occlusive disease of the lower extremities is commonly observed in patients with chronic kidney disease (CKD...
Detailed Description
Study Population and Data Source This is a cross-sectional, single-center study which will be conducted in the Dialysis Center of Tungs' Taichung MetroHarbor Hospital (TTMHH) in the coastal region of...
Eligibility Criteria
Inclusion
- Both sexes aged 20 years or over
- Received stable hemodialysis at least 3 months.
- Written informed consent.
Exclusion
- decompensated cirrhosis.
- neoplastic diseases.
- incomplete data.
- receiving hemodialysis \< 3 months and active infection.
Key Trial Info
Start Date :
June 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 31 2022
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT05256004
Start Date
June 1 2022
End Date
December 31 2022
Last Update
February 22 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Tungs' Taichung MetroHarbour Hospital
Taichung, Taiwan